Drug Profile
Research programme: G-protein coupled receptor-targeting antibodies - Pfizer/Ab Initio Biotherapeutics
Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Ab Initio Biotherapeutics
- Developer Ab Initio Biotherapeutics; Pfizer
- Class Antibodies; Cardiovascular therapies
- Mechanism of Action G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Endocrine disorders; Gastrointestinal disorders; Neurological disorders
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for research development in Cardiovascular-disorders in USA
- 28 Jan 2021 No recent reports of development identified for research development in Endocrine-disorders in USA
- 28 Jan 2021 No recent reports of development identified for research development in Gastrointestinal-disorders in USA